cost-effectiveness Archives -

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

https://pharmaphorum.com/news/nice-rejects-sanofis-cablivi-for-rare-blood-disorder-ttp/

Study sets benchmark for cost of repurposed coronavirus drugs

https://pharmaphorum.com/news/study-sets-benchmark-for-cost-of-repurposed-coronavirus-drugs/

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

https://pharmaphorum.com/market-access-2/nice-backs-nhs-funding-for-roches-kadcyla-in-early-breast-cancer-use/

NICE rejects Roche’s Polivy combination in advanced lymphoma

https://pharmaphorum.com/news/nice-rejects-roches-polivy/

Child with rare disease takes NICE to court over access to life-changing therapy

https://pharmaphorum.com/news/child-with-rare-disease-takes-nice-to-court-over-access-to-life-changing-therapy/

UK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMC

https://pharmaphorum.com/news/uks-nhs-to-fund-shionogis-mulpleo-after-backing-from-nice-and-smc/

ICER says ‘marginal’ benefits for AbbVie’s new RA drug

https://pharmaphorum.com/news/icer-says-marginal-benefits-for-abbvies-new-ra-drug/

After two decades taking on pharma over price, Sir Andrew Dillon steps down from NICE

https://pharmaphorum.com/news/after-two-decades-taking-on-pharma-over-price-sir-andrew-dillon-steps-down-from-nice/

Scotland’s cost regulator rejects Vertex cystic fibrosis drugs

https://pharmaphorum.com/news/scotlands-cost-regulator-rejects-vertex-cystic-fibrosis-drugs/

Search